ALLO-501,allo-501A
allogene therapeutics
['allogene therap']
today we presented data demonstrating the potential of allo-501/501a to generate deep, durable responses similar to approved autologous therapies in patients with #lbcl at the #asco annual meeting.
We are a clinical-stage biotechnology company pioneering the development of allogeneic CAR T(“AlloCAR T™”) products for cancer. Guidelines: https://t.co/QnzUmwSa1w